Indometacin - Iroko Pharmaceuticals

Drug Profile

Indometacin - Iroko Pharmaceuticals

Alternative Names: Indomethacin; Indomethacin nano-formulation - Iroko Pharmaceuticals; IP-940; Lower-dose submicron indomethacin - Iroko Pharmaceuticals; Submicron indomethacin - Iroko Pharmaceuticals; Tiforbex; Tivorbex

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iCeutica
  • Developer Iroko Pharmaceuticals
  • Class Analgesics; Antirheumatics; Chlorobenzenes; Indoles; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute pain
  • Phase II Postoperative pain

Most Recent Events

  • 01 Jan 2017 Iroko Pharmaceuticals completes a phase IIa trial in Postoperative pain (In children, In adolescents) in USA (PO) (NCT02633969)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 Phase-II clinical trials in Postoperative pain (In children, In adolescents) in USA (PO) (NCT02633969)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top